NKTR Nektar Therapeutics

36.51
-1.49  -4%
Previous Close 38
Open 37.45
Price To Book 3.53
Market Cap 6319341784
Shares 173,085,231
Volume 1,705,663
Short Ratio
Av. Daily Volume 2,566,846

NewsSee all news

  1. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  2. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – NKTR
  3. INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  4. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CWH, HON, DY, ALGN and NKTR
  5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline - December 31, 2018

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167941
  2. 8-K - Current report 181166628
  3. 8-K - Current report 181098372
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181002999
  5. 8-K - Current report 181001529

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data at SITC November 2018 noted ORR 53%.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-02
Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 commencement of dosing announced September 12, 2017. Initial data presented at ASCO 2018
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
PDUFA date May 28, 2019.
NKTR-181
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1/2 trial initiation announced April 11, 2018.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b initiation announced May 8, 2018.
NKTR-358
Systemic lupus erythematosus (SLE)

Latest News

  1. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  2. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – NKTR
  3. INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  4. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CWH, HON, DY, ALGN and NKTR
  5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) & Lead Plaintiff Deadline - December 31, 2018
  6. IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  7. CLASS ACTION UPDATE for IGCC, NKTR and SYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  8. Nektar Therapeutics (NKTR): Are Hedge Funds Right About This Stock?
  9. Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Jianpu, Nektar, Honeywell, and Fitbit and Encourages Investors to Contact the Firm
  10. Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit against Nektar Therapeutics, Inc.
  11. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm
  12. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, IGCC, NKTR, TSRO and APHA
  13. 8 Stocks With High Sharpe Ratios to Stomach Volatility
  14. SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm
  15. NKTR NOTICE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action Seeking Investor Losses– NKTR
  16. Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Nektar Therapeutics, Inc.
  17. SHAREHOLDER ALERT: COST NKTR FIT RBBN SONS MGI ATUS CMCM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  18. SHAREHOLDER DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167941
  2. 8-K - Current report 181166628
  3. 8-K - Current report 181098372
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181002999
  5. 8-K - Current report 181001529
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18945948
  7. S-8 - Securities to be offered to employees in employee benefit plans 18929601
  8. 8-K - Current report 18922373
  9. 8-K - Current report 18884730
  10. 8-K - Current report 18876958